Search Site
Home >> Research Area >>Proteases/Proteasome>>HSP >> 17-AAG (KOS953)
17-AAG (KOS953)Hsp90 inhibitor

17-AAG (KOS953)

Catalog No. BCC2121
Size Price Stock
10mM (in 1mL DMSO) $70.00 In stock
10mg $60.00 In stock
50mg $175.00 In stock
100mg $250.00 In stock
200mg $350.00 In stock
Related Products

Organizitions Citing Our Products recently


Calcutta University

University of Minnesota

University of Maryland School of Medicine

University of Illinois at Chicago

The Ohio State University

University of Zurich

Harvard University

Colorado State University

Auburn University

Yale University

Worcester Polytechnic Institute

Washington State University

Stanford University

University of Leipzig

Universidade da Beira Interior

The Institute of Cancer Research

Heidelberg University

University of Amsterdam

University of Auckland
TsingHua University
TsingHua University
The University of Michigan
The University of Michigan
Miami University
Miami University
Jilin University
Jilin University
Fudan University
Fudan University
Wuhan University
Wuhan University
Sun Yat-sen University
Sun Yat-sen University
Universite de Paris
Universite de Paris

Quality Control of 17-AAG (KOS953)

Chemical structure

17-AAG (KOS953)

Biological Activity of 17-AAG (KOS953)

Inhibitor of heat shock protein 90 (Hsp90) chaperone activity, and an analog of geldanamycin. Subsequently inhibits the activity of oncogenic proteins such as p185erbB-2 (IC50 = 31 nM), N-ras, Ki-ras and c-Akt. Antitumor in vivo. Also protects neuroprogenitor cells against stress-induced apoptosis at low concentrations (10 nM) in vitro.


Cell experiment: [1]

Cell lines

HT29, HCT116, KM12 and HCT15 cells

Preparation method

The solubility of this compound in DMSO is >10 mM. General tips for obtaining a higher concentration: Please warm the tube at 37 °C for 10 minutes and/or shake it in the ultrasonic bath for a while.Stock solution can be stored below -20°C for several months.

Reacting condition

IC50: 0.2 μM (HT29), 0.8 μM (HCT116), 0.9 μM (KM12) and 46 μM (HCT15) 24 hours


The cells were treated with a range of 17-AAG concentrations for 24 h and then cultured in the absence of 17-AAG for an additional 48 h. 17-AAG showed antitumor activity in these four human colon adenocarcinoma cell lines and reduced cell viabilities dose-dependently. The IC50 values for HT29, HCT116, KM12 and HCT15 cells are 0.2, 0.8, 0.9 and 46 μM, respectively.

Animal experiment: [2]

Animal models

Old nu/nu athymic mice (male with CWR22 xenograft, female with CWR22R or CWRSA6 xenograft)

Dosage form

Intraperitoneal injection, 50 mg/kg


Both continuous and intermittent dosing schedules were studied. The “continuous” dosing schedule involved exposure to drug 5 days/week for 3 consecutive weeks. In the “intermittent” schedule, mice were treated with one 5-day cycle and then monitored for tumor progression. At progression, mice were treated with a second 5-day cycle of drug. Both regimens caused a dose-dependent delay in xenograft tumor growth in all three models. With the continuous schedule, 50 mg/kg 17-AAG caused 80% growth inhibition of CWRSA6 tumor growth when assessed on the day the controls required sacrifice. With the intermittent schedule, 17-AAG caused 87% growth inhibition of CWRSA6 tumor growth. Similar results were noted with the parental CWR22 model and with a second androgen-independent subline CWR22R.

Other notes

Please test the solubility of all compounds indoor, and the actual solubility may slightly differ with the theoretical value. This is caused by an experimental system error and it is normal.


[1] Hostein I, Robertson D, DiStefano F, et al. Inhibition of signal transduction by the Hsp90 inhibitor 17-allylamino-17-demethoxygeldanamycin results in cytostasis and apoptosis. Cancer Research, 2001, 61(10): 4003-4009.

[2] Solit D B, Zheng F F, Drobnjak M, et al. 17-Allylamino-17-demethoxygeldanamycin induces the degradation of androgen receptor and HER-2/neu and inhibits the growth of prostate cancer xenografts. Clinical cancer research, 2002, 8(5): 986-993.

17-AAG (KOS953) Dilution Calculator

Concentration (start)
Volume (start)
Concentration (final)
Volume (final)


17-AAG (KOS953) Molarity Calculator



Chemical Properties of 17-AAG (KOS953)

Cas No. 75747-14-7 SDF Download SDF
Synonyms NSC 330507, 17-(Allylamino)-17-demethoxygeldanamycin, Tanespimycin
SMILES CO[C@@H]1C[C@H](C)CC2=C(NCC=C)C(=O)C=C(NC(=O)C(=C/C=C/[C@@H](OC)[C@H](OC(N)=O)/C(=C/[C@@H](C)[C@@H]1O)C)C)C2=O
Standard InChI InChI=1S/C31H43N3O8/c1-8-12-33-26-21-13-17(2)14-25(41-7)27(36)19(4)15-20(5)29(42-31(32)39)24(40-6)11-9-10-18(3)30(38)34-22(28(21)37)16-23(26)35/h8-11,15-17,19,24-25,27,29,33,36H,1,12-14H2,2-7H3,(H2,32,39)(H,34,38)/b11-9+,18-10-,20-15+/t17-,19-,24-,25-,27+,29-/m1/s1
Formula C31H43N3O8 M.Wt 585.7
Solubility Soluble to 100 mM in DMSO
Storage Desiccate at -20°C
General tips For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months.
Shipping Condition Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other courier with RT , or blue ice upon request.

Preparing Stock Solutions of 17-AAG (KOS953)

1 mg 5 mg 10 mg 20 mg 25 mg
1 mM 1.7074 mL 8.5368 mL 17.0736 mL 34.1472 mL 42.684 mL
5 mM 0.3415 mL 1.7074 mL 3.4147 mL 6.8294 mL 8.5368 mL
10 mM 0.1707 mL 0.8537 mL 1.7074 mL 3.4147 mL 4.2684 mL
50 mM 0.0341 mL 0.1707 mL 0.3415 mL 0.6829 mL 0.8537 mL
100 mM 0.0171 mL 0.0854 mL 0.1707 mL 0.3415 mL 0.4268 mL
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations.

Research Update of 17-AAG (KOS953)

1. Mode of cell death induced by the HSP90 inhibitor 17-AAG (tanespimycin) is dependent on the expression of pro-apoptotic BAX. Oncotarget. 2013 Nov;4(11):1963-75.
17-AAG induced BAX-dependent apoptosis at pharmacologically relevant concentrations in BAX knockout HCT116 human colon carcinoma cells both in vitro and in tumor xenografts in vivo, where 17-AAG predominantly inhibited cell proliferation rather than promoting cell death.
4. Combined delivery of paclitaxel and tanespimycin via micellar nanocarriers: pharmacokinetics, efficacy and metabolomic analysis. PLoS One. 2013;8(3):e58619. doi: 10.1371/journal.pone.0058619. Epub 2013 Mar 7.
A serious disadvantage in the promising Paclitaxel/17-AAG combination cancer therapy is the requirement of large quantities of toxic organic surfactants and solvents to solubilize the drug.
5. Molecular mechanism of 17-allylamino-17-demethoxygeldanamycin (17-AAG)-induced AXL receptor tyrosine kinase degradation. J Biol Chem. 2013 Jun 14;288(24):17481-94. doi: 10.1074/jbc.M112.439422. Epub 2013 Apr 29.
17-AAG induced the down-regulation of AXL expression in a time- and dose-dependent manner through promoting AXL polyubiquitinlation and subsequent proteasomal degradation, in which 17-AAG requires AXL intracellular domain regardless of AXL receptor phosphorylation.

Background on 17-AAG (KOS953)

17-AAG is a potent inhibitor of HSP90 with IC50 value of 6 nM in BT474 cells [1].

17-AAG is a synthetic analogue developed from geldanamycin which was found to have significant hepatic toxicity. 17-AAG has an improved toxicity profile and has no hepatic toxicity. 17-AAG can bind to HSP90 and destabilize the client proteins such as HER2, Raf-1, p53 and MAPK signaling. In Multiple myeloma (MM) cells, 17-AAG treatment inhibited cell proliferation and survival. The combination treatment of 17-AAG and bortezomib induced apoptosis in primary MM cells resistant to doxorubicin and bortezomib. The combination of 17-AAG and trastuzumab reduced the expression of ErbB2 in breast cancer cells overexpressing ErbB2. 17-AAG also showed efficacy in thyroid cancer cells and Hodgkin lymphoma cells. Besides that, 17-AAG was found to increased apoptosis in human melanoma xenografts. 17-AAG is now in phase II clinical studies [2].

[1] Kamal A, Thao L, Sensintaffar J, et al. A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors[J]. Nature, 2003, 425(6956): 407-410..
[2] Dimopoulos M A, Mitsiades C S, Anderson K C, et al. Tanespimycin as antitumor therapy. Clinical Lymphoma Myeloma and Leukemia, 2011, 11(1): 17-22


17-AAG (KOS953),75747-14-7,NSC 330507, 17-(Allylamino)-17-demethoxygeldanamycin, Tanespimycin,Proteases/Proteasome,HSP, supplier, inhibitor,Antagonist,Blocker,Modulator,Agonist, activators, activates, potent, BioCrick

Online Inquiry

Fill out the information below

* Required Fields